47 related articles for article (PubMed ID: 24916728)
1. Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample.
Irene R; Luis MA; Helena DC; David P; Ramon DJ; Inmaculada G
Int J Psychiatry Clin Pract; 2009; 13(2):100-8. PubMed ID: 24916728
[TBL] [Abstract][Full Text] [Related]
2. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques.
Perahia DG; Quail D; Desaiah D; Corruble E; Fava M
J Clin Psychiatry; 2008 Jan; 69(1):95-105. PubMed ID: 18312043
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
6. Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy.
Kuga A; Otsubo T; Tsuji T; Hayashi S; Imagawa H; Fujikoshi S; Escobar R
Neuropsychiatr Dis Treat; 2019; 15():809-817. PubMed ID: 31040680
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
8. An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life.
Kuga A; Tsuji T; Hayashi S; Fujikoshi S; Tokuoka H; Yoshikawa A; Escobar R; Tanaka K; Azekawa T
Neuropsychiatr Dis Treat; 2017; 13():2115-2124. PubMed ID: 28831260
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
11. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV
Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
[TBL] [Abstract][Full Text] [Related]
15. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava M; McGrath PJ; Sheu WP;
J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
17. An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis.
Kuga A; Tsuji T; Hayashi S; Matsubara M; Fujikoshi S; Tokuoka H; Yoshikawa A; Escobar R; Tanaka K; Azekawa T
Neuropsychiatr Dis Treat; 2017; 13():2105-2114. PubMed ID: 28831259
[TBL] [Abstract][Full Text] [Related]
18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
19. Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Novick D; Montgomery W; Haro JM; Moneta MV; Zhu G; Yue L; Hong J; Dueñas H; Brugnoli R
Neuropsychiatr Dis Treat; 2016; 12():383-92. PubMed ID: 26966361
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting.
Hong J; Novick D; Montgomery W; Moneta MV; Dueñas H; Peng X; Haro JM
Patient Prefer Adherence; 2015; 9():1481-90. PubMed ID: 26527865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
